Minerva Biotechnologies Corporation
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
4
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 18, 2027The maintenance fee for A Method of Treating an NME7 Expressing Cancer with a Peptide (US 11,702,483) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 2 fees due Mar 5 to 24, 2027 · next Mar 5
- 2 fees due Aug 13, 2027
- 1 fee due Sep 19, 2027The maintenance fee for Method of screening for agents for differentiating stem cells (US 11,931,347) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
- 2 fees due Nov 7, 2027
Recent changes
- 1 term has ended since Aug 23, 2026
- Oct 14 US 8,859,495 Methods for Stimulating or Enhancing Proliferation of Non-Tumorous Cells Expressing MUC1 Receptors · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,700,715 | Diagnostic Tumor Markers, Drug Screening for Tumorigenesis Inhibition, and Compositions and Methods for Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 11,898,160 | Method for maintaining pluripotency in cells In force · USPTO record | In force | USPTO record | |
| US 8,535,944 | Culturing embryonic stem cells, embryonic stem-like cells, or induced pluripotent stem cells with a Muc1 or Muc1* ligand In force · USPTO record | In force | USPTO record | |
| US 11,560,435 | MUC1* Antibodies In force · Low confidence | In force | Low confidence | |
| US 10,724,027 | Method for making pluripotent stem cells In force · USPTO record | In force | USPTO record | |
| US 12,195,728 | Method for making pluripotent stem cells In force · USPTO record | In force | USPTO record | |
| US 11,976,295 | Media for Stem Cell Proliferation and Induction In force · Medium confidence | In force | Medium confidence | |
| US 9,932,407 | Stem cell enhancing therapeutics In force · USPTO record | In force | USPTO record | |
| US 11,702,483 | A Method of Treating an NME7 Expressing Cancer with a Peptide In force · Medium confidence | In force | Medium confidence | |
| US 12,479,928 | Anti-Cancer Peptide In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 28: 3 lapsed for an unpaid fee · 7 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending · 10 abandoned · 37 no status recorded